Fox Run Management L.L.C. Invests $1.18 Million in Bristol Myers Squibb Company $BMY

Fox Run Management L.L.C. purchased a new stake in Bristol Myers Squibb Company (NYSE:BMY) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 26,138 shares of the biopharmaceutical company’s stock, valued at approximately $1,179,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of BMY. Brighton Jones LLC grew its holdings in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after buying an additional 4,935 shares during the last quarter. Sivia Capital Partners LLC lifted its position in Bristol Myers Squibb by 59.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock valued at $346,000 after acquiring an additional 2,786 shares in the last quarter. United Bank increased its holdings in Bristol Myers Squibb by 15.0% during the 2nd quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after purchasing an additional 3,277 shares in the last quarter. Rossby Financial LCC increased its holdings in Bristol Myers Squibb by 25.6% during the 2nd quarter. Rossby Financial LCC now owns 2,560 shares of the biopharmaceutical company’s stock worth $119,000 after purchasing an additional 521 shares in the last quarter. Finally, Howard Capital Management Inc. raised its stake in shares of Bristol Myers Squibb by 24.6% in the second quarter. Howard Capital Management Inc. now owns 23,215 shares of the biopharmaceutical company’s stock worth $1,075,000 after purchasing an additional 4,585 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on BMY. Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research report on Tuesday. They set a “sector perform” rating and a $60.00 target price on the stock. HSBC restated a “hold” rating and set a $53.00 price objective on shares of Bristol Myers Squibb in a research note on Wednesday, December 10th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 3rd. Guggenheim reissued a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $60.71.

Bristol Myers Squibb Trading Down 0.4%

Shares of Bristol Myers Squibb stock opened at $61.32 on Thursday. The firm has a market cap of $124.88 billion, a PE ratio of 17.78, a P/E/G ratio of 0.18 and a beta of 0.29. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The stock has a fifty day moving average price of $56.66 and a 200-day moving average price of $50.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. Bristol Myers Squibb’s quarterly revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. The ex-dividend date was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.